Sunscreen Innovation Act Illuminates ‘Good Things’ For OTC Monograph Reform
This article was originally published in The Tan Sheet
The Sunscreen Innovation Act’s more efficient process provides a model for OTC monograph reform, says nonprescription drugs office chief Theresa Michele. At a CHPA conference, she says a key change under the act is eliminating some administrative steps required for other monograph proposals.
You may also be interested in...
FDA denies sunscreen TEAS for L'Oreal and Merck & Co., citing data gaps, according to proposed orders. Proponents of launching additional ingredients say the decisions point to continued gridlock in changing FDA’s OTC sunscreen monograph.
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.